Stabilis

Metronidazole



Noms commerciaux

Amrizole	Arabie Saoudite, Egypte, Emirats Arabes Unis
Anaerobex	Autriche
Anaeromet	Luxembourg
Antibactrol	Chili
Bactrizol	Vénézuela
Colpocin	Grèce
Deflamon	Italie
Dumozol	Egypte, Portugal
Efloran	Croatie, Slovénie
Elyzol	Arabie Saoudite
Emedal	Grèce
Femagin	Malaisie
Flagyl	Afrique du sud, Belgique, Brésil, Chili, Colombie, Danemark, Egypte, Equateur, Espagne, Etats Unis d'Amérique, France, Grande Bretagne, Grèce, Irlande, Islande, Maroc, Norvège, Pays bas, Pérou, Suède, Suisse, Turquie
Flaxtec	Mexique
Flazol	Egypte
Flegyl	Vénézuela
Gnostol	Grèce
Klion	Hongrie
Medazol	Croatie
Metrolag	Suisse
Metrolyl	Grande Bretagne
Metronidazole	Australie, Canada
Nidazol	Turquie
Novakom	Turquie

Stabilité en mélange

		2 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20	630
		2.6 mg/ml	25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	2228
	∅	2,5 mg/ml	23°C		Levofloxacine : 2,5 mg/ml	3	1988

	∅	5 mg/ml	25°C		Cefoxitin sodium : 30 mg/ml	2	631
	∅	5 mg/ml	25°C		Cefoxitin sodium : 30 mg/ml	2	631
	∅	5 mg/ml	25°C		Moxalactam : 20 mg/ml	2	631
	∅	5 mg/ml	25°C		Penicillin G potassium : 0,2 MUI/ml	3	631
	∅	5 mg/ml	25°C		Cefazolin sodium : 10 mg/ml	7	631
	∅	5 mg/ml	25°C		Hydrocortisone sodium succinate : 10 mg/ml	7	631
	∅	5 mg/ml	25°C		Ampicillin sodium : 20 mg/ml	22	631
	∅	5 mg/ml	5°C		Ampicillin sodium : 20 mg/ml	12	631
	∅	5 mg/ml	5°C		Cefazolin sodium : 10 mg/ml	12	631
	∅	5 mg/ml	5°C		Cefoxitin sodium : 30 mg/ml	12	631
	∅	5 mg/ml	5°C		Cefalotin sodium : 20 mg/ml	12	631
	∅	5 mg/ml	5°C		Hydrocortisone sodium succinate : 10 mg/ml	12	631
	∅	5 mg/ml	5°C		Penicillin G potassium : 0,2 MUI/ml	12	631
	∅	5 mg/ml	5°C		Moxalactam : 20 mg/ml	12	631
	∅	5 mg/ml	8°C		Cefazolin sodium : 10 mg/ml	3	671
PVC		7,5 mg/ml	24-26°C	?	Ceftriaxone disodium : 10 mg/ml	24	11
PVC		4 mg/ml	25°C		Ciprofloxacin lactate : 1,5 mg/ml	48	434
PVC		7,5 mg/ml	4-6°C		Ceftriaxone disodium : 10 mg/ml	72	11
PVC		4 mg/ml	4°C		Ciprofloxacin lactate : 1,5 mg/ml	48	434
PVC		5 mg/ml	28°C	?	Cefotaxime sodium : 10 mg/ml	12	281
PVC		5 mg/ml	5°C		Cefotaxime sodium : 10 mg/ml	96	281
PVC	∅	5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 2,5 & 20 mg/ml	2	1605
PVC	∅	5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 5 mg/ml	4	1605
PVC	∅	5 mg/ml	22°C-24°C		Cefepime dihydrochloride : 10 mg/ml	5	1605
PVC	∅	5 mg/ml	25°C	?	Ceftriaxone disodium : 10 mg/ml	3	649
PVC	∅	5 mg/ml	25°C	?	Ceftizoxime sodium : 10 mg/ml	3	267
PVC	∅	5 mg/ml	4°C		Cefuroxime sodium : 7,5 mg/ml	7	961
PVC	∅	5 mg/ml	4°C		Ceftizoxime sodium : 10 mg/ml	14	267
PVC	∅	5 mg/ml	4°C		Cefepime dihydrochloride : 2,5 >> 20 mg/ml	7	1605
PVC	∅	5 mg/ml	8°C	?	Ceftizoxime sodium : 10 mg/ml	72	282
PVC	∅	5 mg/ml	8°C	?	Ceftriaxone disodium : 10 mg/ml	72	282
PVC	∅	5 mg/ml	8°C	?	Ceftazidime : 10 mg/ml	72	282
?	∅	4,1 mg/ml	20°C		Cefamandole nafate : 16,6 mg/ml	4	1479

?	∅	5 mg/ml	25°C		Piperacillin sodium : 40 mg/ml	4	1692

Facteur influençant la stabilité

	10				3594

Compatibilités

		Metronidazole : 5 mg/ml Aciclovir sodium : 5 mg/ml	◆	336
		Metronidazole : 5 mg/ml Allopurinol sodium : 3 mg/ml	▲	307
		Metronidazole : 5 mg/ml Amifostine : 10 mg/ml	◆	3
		Metronidazole Amikacin sulfate		3594
		Metronidazole : 5 mg/ml Amikacin sulfate : 5 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml	▲◆	385
		Metronidazole : 5 mg/ml Amiodarone hydrochloride : 6 mg/ml	◆	1611
		Metronidazole : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Metronidazole : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml	◆	921
		Metronidazole Ampicillin sodium		3594
		Metronidazole : 5 mg/ml Ampicillin sodium : 20 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Ampicillin sodium : 20 mg/ml	∅	631
		Metronidazole : 5 mg/ml Anidulafungin : 0.5 mg/ml	◆	1982
		Metronidazole : 5 mg/ml Atenolol : 0,1 mg/ml	▲	4698
12		Metronidazole : 5 mg/ml Aztreonam : 10 & 20 mg/ml	∅	19
?		Metronidazole Aztreonam		3547
4		Metronidazole : 5 mg/ml Aztreonam : 40 mg/ml	◆	99
		Metronidazole : 5 mg/ml Bivalirudin : 5 mg/ml	◆	1713
		Metronidazole : 2.5 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml	▲	3976

		Metronidazole : 5 mg/ml Caffeine : 10 mg/ml	∅	3964
		Metronidazole : 5 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Metronidazole : 5 mg/ml Caspofungin acetate : 0.5 mg/ml	▲	2233
		Metronidazole Cefalotin sodium		3594
		Metronidazole : 5 mg/ml Cefalotin sodium : 20 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Cefalotin sodium : 20 mg/ml	∅	631
		Metronidazole : 4.17 mg/ml Cefamandole nafate : 16.67 mg/ml	∅	1479
		Metronidazole : 5 mg/ml Cefamandole nafate : 20 mg/ml	∅	1035
		Metronidazole Cefamandole nafate		3594
		Metronidazole : 5 mg/ml Cefazolin sodium : 10 mg/ml	∅	631
		Metronidazole : 5 mg/ml Cefazolin sodium : 10 mg/ml	∅	1035
		Metronidazole Cefazolin sodium		3594
		Metronidazole Cefepime dihydrochloride		3548
		Metronidazole : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲♦	4528
		Metronidazole : 5 mg/ml Cefotaxime sodium : 10 mg/ml	∅	281
		Metronidazole Cefotaxime sodium		3594
		Metronidazole : 5 mg/ml Cefotaxime sodium : 20 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Cefoxitin sodium : 30 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Cefoxitin sodium : 30 mg/ml	∅	631
		Metronidazole : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Metronidazole : 5 mg/ml		1415
		Metronidazole Cefoxitin sodium		3594
		Metronidazole : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	▲♦	2269
		Metronidazole : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	▲♦	3828
		Metronidazole : 5 mg/ml	RL	4603
		Metronidazole : 5 mg/ml		4440
		Metronidazole : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	▲♦	3249

		Metronidazole : 5 mg/ml		3967
		Metronidazole : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Metronidazole : 5 mg/ml Ceftazidime : 10 mg/ml	∅	282
		Metronidazole : 5 mg/ml Ceftizoxime sodium : 10 mg/ml	∅	282
		Metronidazole : 5 mg/ml Ceftizoxime sodium : 10 mg/ml	∅	267
		Metronidazole : 5 mg/ml		3948
		Metronidazole : 5 mg/ml Ceftriaxone disodium : 10 mg/ml	∅	282
		Metronidazole : 7.5 mg/ml Ceftriaxone disodium : 10 mg/ml		11
		Metronidazole : 5 mg/ml Ceftriaxone disodium : 10 mg/ml	∅	649
		Metronidazole : 15 mg/ml Ceftriaxone disodium : 20 mg/ml		11
		Metronidazole Cefuroxime sodium		3594
		Metronidazole : 5 mg/ml Cefuroxime sodium : 7,5 mg/ml	∅	961
		Metronidazole : 5 mg/ml Chloramphenicol sodium succinate : 10 mg/ml	∅	1035
		Metronidazole Chloramphenicol sodium succinate		3594
		Metronidazole : 2.5 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Metronidazole : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
		Metronidazole : 4 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Metronidazole : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Metronidazole : 5 mg/ml Clindamycin phosphate : 10 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Metronidazole Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Metronidazole	10	3594
		Metronidazole : 5 mg/ml		301
		Metronidazole Clindamycin phosphate		3594
		Metronidazole : 5 mg/ml Defibrotide : 8 mg/ml		3728
		Metronidazole : 5 & 8 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Metronidazole Dimenhydrinate		2087

	✓	Metronidazole : 5 mg/ml		939
	✓	Metronidazole : 5 mg/ml		3948
	✓	Metronidazole : 5 mg/ml Dexmedetomidine : 4 µg/ml		1712
	✓	Metronidazole : 5 mg/ml		316
	✓	Metronidazole : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
	✓	Metronidazole : 5 mg/ml Dopamine hydrochloride : 0.8 mg/ml		132
	✓	Metronidazole : 5 mg/ml Doripenem : 5 mg/ml		2262
	✓	Metronidazole : 5 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
	✓	Metronidazole : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	✓	Metronidazole : 5 mg/ml Enalaprilate : 0.05 mg/ml		1315
	✓	Metronidazole : 5 mg/ml Eravacycline : 0,6 mg/ml		4434
	✓	Metronidazole : 5 mg/ml Esmolol hydrochloride : 10 mg/ml		384
	✓	Metronidazole : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	✓	Metronidazole : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	✓	Metronidazole : 5 mg/ml Fentanyl citrate : 50 µg/ml		63
		Metronidazole : 5 mg/ml Filgrastim : 30 µg/ml		244
	✓	Metronidazole : 5 mg/ml Fluconazole : 2 mg/ml		496
	✓	Metronidazole : 5 mg/ml Fluconazole : 2 mg/ml	∅	256
	✓	Metronidazole : 5 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
	✓	Metronidazole : 5 mg/ml Foscarnet sodium : 24 mg/ml		1135
	✓	Metronidazole : 5 mg/ml Fosfomycin : 30 mg/ml		4055
	✓	Metronidazole : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	✓	Metronidazole : 5 mg/ml Gentamicin sulfate : 0,8 & 1,2 mg/ml	∅	1243
	✓	Metronidazole Gentamicin sulfate		3594
	✓	Metronidazole : 5 mg/ml Gentamicin sulfate : 0.8 mg/ml	∅	1035
	✓	Metronidazole : 5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	✓	Metronidazole : 5 mg/ml Heparin sodium : 50 UI/ml	∅	317

		Metronidazole : 5 mg/ml Hetastarch : 60 mg/ml		1721
		Metronidazole : 5 mg/ml Hydrocortisone sodium succinate : 10 mg/ml	∅	631
		Metronidazole : 5 mg/ml Hydrocortisone sodium succinate : 10 mg/ml	∅	1035
		Metronidazole Hydrocortisone sodium succinate		3594
		Metronidazole : 5 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml	◆	405
		Metronidazole : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Metronidazole : 5 mg/ml Labetalol hydrochloride : 1 mg/ml	◆	386
		Metronidazole : 5 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
		Metronidazole : 5 mg/ml Levofloxacine : 5 mg/ml	∅	1988
		Metronidazole : 5 mg/ml Linezolid : 2 mg/ml	∅	1925
		Metronidazole : 5 mg/ml Lorazepam : 0.33 mg/ml	▲	186
		Metronidazole : 2 mg/ml Magnesium sulfate : 10 & 20 mg/ml	◆	630
		Metronidazole : 5 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml	◆	1047
		Metronidazole : 5 mg/ml Melphalan : 0.1 mg/ml	▲	169
		Metronidazole : 5 mg/ml Meropenem : 1 >> 50 mg/ml	▲	266
		Metronidazole : 5 mg/ml Meropenem : 50 mg/ml	●	4319
		Metronidazole : 5 mg/ml Methylprednisolone sodium succinate : 5 mg/ml	◆	132
		Metronidazole : 5 mg/ml Midazolam hydrochloride : 1 mg/ml	◆	176
		Metronidazole : 5 mg/ml Midazolam hydrochloride : 5 mg/ml	∅	186
		Metronidazole : 5 mg/ml Midazolam hydrochloride : 0.05 >> 0.4 mg/ml	∅	1888
		Metronidazole : 5 mg/ml Morphine sulfate : 1 mg/ml	◆	405
		Metronidazole : 5 mg/ml Moxalactam : 20 mg/ml	∅	631
		Metronidazole : 5 mg/ml Moxalactam : 20 mg/ml	∅	1035
		Metronidazole : 5 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Metronidazole : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Metronidazole : 5 mg/ml Netilmicin sulfate : 1 mg/ml	▲	958

		Metronidazole Netilmicin sulfate		3594
		Metronidazole : 5 mg/ml Netilmicin sulfate : 1.4 mg/ml	∅	1035
		Metronidazole : 5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Metronidazole : 5 mg/ml Oritavancin : 2 mg/ml		3152
		Metronidazole : 5 mg/ml Oritavancin : 0.8 >>1.2 mg/ml		3152
		Metronidazole : 5 mg/ml Palonosetron hydrochloride : 50 µg/ml		2228
15'		Metronidazole Pantoprazole sodium		2090
		Metronidazole : 5 mg/ml Paracetamol : 10 mg/ml		4742
		Metronidazole : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Metronidazole : 5 mg/ml Penicillin G potassium : 0.2 MUI/ml	∅	631
		Metronidazole : 5 mg/ml Penicillin G potassium : 0.012 MUI/ml	∅	1035
?		Metronidazole Penicillin G potassium		3594
		Metronidazole : 5 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Metronidazole : 5 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Metronidazole : 2,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Metronidazole : 5 mg/ml Piperacillin sodium : 40 mg/ml	∅	1692
		Metronidazole : 5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Metronidazole : 5 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Metronidazole : 5 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Metronidazole : 5 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Metronidazole : 5 mg/ml Sargramostim : 10 µg/ml		335
		Metronidazole : 5 mg/ml Tacrolimus : 1000 µg/ml		479
		Metronidazole : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Metronidazole : 5 mg/ml Teniposide : 0.1 mg/ml		905
		Metronidazole : 5 mg/ml Theophylline : 4 mg/ml	∅	317
		Metronidazole : 5 mg/ml Thiopental sodium : 25 mg/ml		3767

		Metronidazole : 5 mg/ml Thiotepa : 1 mg/ml		249
		Metronidazole : 5 mg/ml Tobramycin sulfate : 0.8 mg/ml	∅	1035
		Metronidazole Tobramycin sulfate		3594
		Metronidazole : 5 mg/ml Vasopressin : 0.2 UI/ml		2017
		Metronidazole : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Metronidazole : 5 mg/ml Warfarin sodium : 2 mg/ml		315

Voie d'administration

Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
11	Revue	Bailey LC, Orosz ST. Stability of ceftriaxone sodium and metronidazole hydrochloride. Am J Health-Syst Pharm 1997 ; 54: 424-427.
19	Revue	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
267	Revue	Nahata MC, Edmonds JJ, Morosco RS. Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25°C. Am J Health-Syst Pharm 1996 ; 53: 1046-1048.
281	Revue	Belliveau PP, Nightingale CH, Quintiliani R. Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 1561-1563.
282	Revue	Rivers TE, Webster AA. Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 2568-2570.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.

299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Revue	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
434	Revue	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
630	Revue	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.

631	Revue	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
649	Revue	Das Gupta V. Stability of ceftriaxone sodium when mixed with metronidazole injection. Int J Pharm Compound 1997 ; 1: 280-281.
671	Revue	Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture. J Parenter Sci Technol 1993 ; 47: 135-137.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
958	Revue	Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. Ann Pharmacotherapy 1990 ; 24: 440-442.
961	Revue	Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. J Clin Pharm Ther 1990 ; 15: 187-196.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1243	Revue	Rovers JP, Meneilly G, Souny PF, Rekhi GS, Drum D. The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures. Can J Hosp Pharm 1989 ; 42: 143-146.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.

1479	Revue	Digel S. Cefamandolnafat und metronidazol. Chemische stabilität in einer mischung zur intravenösen infusion. Krankenhauspharmazie 1995 ; 1: 9-12.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1605	Revue	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. Hosp Pharm 2000 ; 35: 1057-1064.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1692	Revue	Messerschmidt W. Pharmazeutische kompatibilität von piperacillin mit metronidazol. Krankenhauspharmazie 1998 ; 19: 226-228.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.

1988	Revue	Sprandel KA, Styrszula DE, Deyo K, Sibley C, Rodvold KA. Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 88-92.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2228	Revue	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3547	Laboratoire	Aztréonam (Azactam®) - Résumé des caractéristiques du produit Sanofi-Aventis France 2011
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013

3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Revue	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.

4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis

Metronidazole



Stabilité des préparations

	1600 mg Metronidazole	OraPlus® >> 100 ml	25°C		90			2702
	1600 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 100 ml	25°C		90			2702
	3000 mg Metronidazole	Sirop simple >> 60 ml	23°C		93			2695
	3000 mg Metronidazole	Orablend® >> 60 ml	23°C		93			2695
	6000 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 120 ml	25°C		60			2441
	6000 mg Metronidazole	OraPlus® / OraSweet SF® (1:1) >> 120 ml	25°C		60			2441
	6000 mg Metronidazole	Sirop de cerise >> 120 ml	25°C		60			2441
	3000 mg Metrogyl®	Oral Mix® >> 60 mL	25°C		90			4375
	3000 mg Metrogyl®	Oral Mix SF® >> 60 mL	25°C		90			4375
	3000 mg ® = ?	Oral Mix® >> 60 mL	25°C		90			4375
	3000 mg ® = ?	Oral Mix SF® >> 60 mL	25°C		90			4375

		2000 mg ® = ?	Glycosides de stéviol 95% 320 mg Acésulfame potassique 320 mg Réducteur d'amertume 0,32 mL Arôme banane 2,4 mL Suspendit® >>80 mL	25°C		180			4575
		4000 mg ® = ?	Glycosides de stéviol 95% 320 mg Acésulfame potassique 320 mg Réducteur d'amertume 0,32 mL Arôme banane 2,4 mL Suspendit® >>80 mL	25°C		180			4575
		3000 mg Metrogyl®	Oral Mix® >> 60 mL	4°C		90			4375
		3000 mg Metrogyl®	Oral Mix SF® >> 60 mL	4°C		90			4375
		3000 mg ® = ?	Oral Mix SF® >> 60 mL	4°C		90			4375
		3000 mg ® = ?	Oral Mix® >> 60 mL	4°C		90			4375
		6000 mg Metronidazole	OraPlus® / OraSweet® (1:1) >> 120 ml	5°C		60			2441
		6000 mg Metronidazole	OraPlus® / OraSweet SF® (1:1) >> 120 m	5°C		60			2441
		6000 mg Metronidazole	Sirop de cerise >> 120 ml	5°C		60			2441
		3000 mg Metronidazole	Sirop simple >> 60 ml	5°C		93			2695
		3000 mg Metronidazole	Orablend® >> 60 ml	5°C		93			2695
		2000 mg ® = ?	Glycosides de stéviol 95% 320 mg Acésulfame potassique 320 mg Réducteur d'amertume 0,32 mL Arôme banane 2,4 mL Suspendit® >>80 mL	5°C		180			4575
		4000 mg ® = ?	Glycosides de stéviol 95% 320 mg Acésulfame potassique 320 mg Réducteur d'amertume 0,32 mL Arôme banane 2,4 mL Suspendit® >>80 mL	5°C		180			4575
		150 mg Metrogyl®	Oral Mix® >> 3 mL	25°C		90			4375
		150 mg Metrogyl®	Oral Mix SF® >> 3 mL	25°C		90			4375
		150 mg ® = ?	Oral Mix SF® >> 3 mL	25°C		90			4375
		150 mg Metrogyl®	Oral Mix® >> 3 mL	4°C		90			4375
		150 mg ® = ?	Oral Mix SF® >> 3 mL	4°C		90			4375
		150 mg Metrogyl®	Oral Mix SF® >> 3 mL	4°C		90			4375
?		30 g ®=? (Parmes pharmaceuticals)	Carboxymethylcellulose sodique 15 g Veegum® 15 g Sorbitol 70% 1200 ml Saccharinate de sodium 1 g POH benzoate de methyle 2 g POH benzoate de propyle 400 mg Arôme ananas Eau distillée >> 2000 ml	25°C	?	90			2663

Bibliographie

	Type	Source
2441	Revue	Allen LV, Jr, Erickson MA, Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2073-2078.
2663	Revue	Alexander KS, Vangala SSKS, Dollimore D. The formulation development and stability of metronidazole suspension. Int J Pharm Compound 1997 ; 1: 200-205.
2695	Revue	Donnelly Ronald F, Ying James. Stability of Metronidazole Suspensions. Int J Pharm Compound 2015 ; 19, 3: 248-251.
2702	Revue	Mathew M, Gupta VD, Bethea C. Stability of metronidazole benzoate in suspensions J Clin Pharm Ther 1994 ; 19, 1: 31-34.
4375	Revue	Jarouche M, Ibrahim M, Pearson J, Venkataya B, Low M, Rowe J. Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets. Int J Pharm Compound 2020 ;24,1:77-82
4575	Revue	Pramar Y, Mandal T, Bostanian L, Le G, Morris T, Richard A. Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt. Int J Pharm Compound 2021 ;25,2:169-175

Dictionnaire

	Antiparasitaire
	Noms commerciaux
	Contenant
	Concentration
	Conservation
	Durée de stabilité
	Verre
	A l'abri de la lumière
?	Non précisée
	Lumière
PVC	Polyvinyl chlorure
	Chlorure de sodium 0,9%
	Facteur influençant la stabilité
	Provoque
	Compatibilités
	Précipitation immédiate
	Turbidité immédiate
	Incompatibilité non précisée
	Instabilité chimique
	Nutrition parentérale (mélange ternaire)
	Nutrition parentérale (mélange binaire)
15'	Précipitation en 15 minutes
24	Turbidité à 24 heures
	Perfusion intraveineuse
	Solution buvable
	Origine
	Biosimilaire
	Poudre
	Comprimés
	Dictionnaire

	Injectable
	Stabilité en mélange
	Solvant
	Température
	Molécule
	Bibliographie
	Glucose 5%
	Heure
∅	Aucun
	Jour
	NaCl 0,9% ou glucose 5%
?	Non précisé
10	Glucose 10%
	Dégradation
	Compatible
	Incompatible
12	Changement de couleur à 12 heures
4	Changement de couleur à 4 heures
RL	Ringer lactate
	Eau pour préparation injectable
	Solvant spécifique
	Changement de couleur
	Voie d'administration
	Bibliographie
	Stabilité des préparations
	Excipient
	Données conflictuelles
	Flacon plastique
	Seringue PP orale